Regulation of Platelet Function in Older Patients With Atrial Fibrillation

NCT07724301 | Not Yet Recruiting

• 1 other identifier: HUM00295130
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this observational study is to learn about the effects of antiplatelet drugs on patients over the age of 80 with atrial fibrillation. The main question it aims to answer is:

• Is platelet reactivity effectively controlled in patients over the age of 80 diagnosed with atrial fibrillation following the Watchman procedure.

Conditions

Atrial Fibrillation; Thrombotic Risk

Keywords

atrial fibrillation; thrombosis; bleeding; elderly over 80; antiplatelet drugs; aspirin; clopidogrel; platelet function

Outcome Measures

Primary Outcomes (1)

• Platelet reactivity

  platelet reactivity will be measured before and after antiplatelet treatment in patients over 80. Outcomes will include 1) platelet aggregation, 2) integrin activation, 3) alpha and dense granule secretion, 4) T-TAS activation, and 5) TEG.

  blood draw will occur prior to Watchman procedure and antiplatelet administration and 90 days following Watchman procedure while patients are taking antiplatelet drugs

Study Arms (1)

Patients with atrial fibrillation over the age of 80

Patients over the age of 80 diagnosed with atrial fibrillation receiving ether aspirin alone or aspirin and clopidogrel

Eligibility Criteria

• Age: 80 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of patients over the age of 80 who have been diagnosed with atrial fibrillation and will receive the Watchman Procedure and receive antiplatelet drugs following procedure.

You may qualify if:

• diagnosed with atrial fibrillation, scheduled for a Watchman Procedure

You may not qualify if:

• Healthy, taking antiplatelet medication

Sponsors & Collaborators

• University of Michigan: lead

MeSH Terms

Conditions

Atrial Fibrillation; Thrombosis; Hemorrhage

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Embolism and Thrombosis; Vascular Diseases

Central Study Contacts

Michael Holinstat, PhD

CONTACT

734-764-4046; mholinst@med.umich.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 20, 2026
• First Posted: July 24, 2026
• Study Start: August 1, 2026
• Primary Completion (Estimated): August 1, 2028
• Study Completion (Estimated): August 1, 2028
• Last Updated: July 24, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share